csirt@kutim:~/threat-intel/cve/CVE-2023-20045

Katalog CVE

CVSS 7.2 · High EPSS 0,96%

Kerentanan Improper Neutralization of Special Elements used in a Command ('Command Injection') pada cisco rv160 vpn router firmware, cisco rv160w wireless-ac vpn router firmware +2 lainnya. Skor CVSS 3.1 7.2 (High) menurut NVD.

Deskripsi (NVD)

A vulnerability in the web-based management interface of Cisco Small Business RV160 and RV260 Series VPN Routers could allow an authenticated, remote attacker to execute arbitrary commands on the underlying operating system of an affected device. This vulnerability is due to insufficient validation of user input. An attacker could exploit this vulnerability by sending a crafted request to the web-based management interface of an affected device. A successful exploit could allow the attacker to execute arbitrary commands using root-level privileges on the affected device. To exploit this vulnerability, the attacker must have valid Administrator-level credentials on the affected device.

Rincian

Terbit di NVD
20 Januari 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
7.2 (High), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-77: Improper Neutralization of Special Elements used in a Command ('Command Injection')
CWE-20: Improper Input Validation
EPSS (30 hari)
0,96% peluang dieksploitasi; lebih tinggi dari 60,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
cisco rv160 vpn router firmware Semua versi sebelum 1.0.01.04
cisco rv160w wireless-ac vpn router firmware Semua versi sebelum 1.0.01.04
cisco rv260 vpn router firmware Semua versi sebelum 1.0.01.04
cisco rv260p vpn router with poe firmware Semua versi sebelum 1.0.01.04

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.